Fixed versus variable dose of prothrombin complex concentrate for counteracting vitamin K antagonist therapy

Abstract

This study suggests that a fixed dose of 1040 IU of F IX may be an effective way to rapidly counteract VKA therapy in our patient population and provides a basis for future research.